Changes in thymosin-alpha(1)content in patients with nonspecific gynecologic diseases depending on inflammation type and efficacy of antiinflammatory and immunomodulating therapy.
Shurlygina. A A; Litvinenko. G G; Dergacheva. T T; Trufakin. V V
Key Findings
- Plasma thymosin‑alpha‑1 levels are lower or altered in patients with nonspecific inflammatory gynecologic diseases compared to healthy donors.
- The circadian (daily) variation of thymosin‑alpha‑1 is disrupted in these patients.
- The degree of change in thymosin‑alpha‑1 levels correlates with the type of inflammation and the effectiveness of anti‑inflammatory/immunomodulating therapy.
Practical Outcomes
- For biohackers interested in immune support, the findings hint that timing (circadian rhythm) could influence how thymosin‑alpha‑1 works, especially if you have ongoing inflammation. However, the research is limited to a specific female patient group, so more data are needed before applying dosing or timing strategies to general health or longevity protocols.
Summary
The study shows that women with inflammatory gynecologic problems have different amounts of the immune‑modulating peptide thymosin‑alpha‑1 in their blood, and those levels change throughout the day. The pattern depends on what kind of inflammation they have and how well their treatment works, suggesting both the amount and timing of thymosin‑alpha‑1 matter for immune regulation.
Abstract
Plasma content of thymosin-alpha(1)and its circadian variations in patients with inflammatory gynecologic diseases differ from those in healthy donors and depend on the type of inflammation and efficacy of treatment. It is concluded that not only the absolute content of thymic hormones, but also their biorhythmic variations are important for immune regulation.
Study Information
pubmed
2000